September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
June 2025 in “Neurology India” Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
3 citations
,
November 2023 in “The Journal of Dermatology”
1 citations
,
May 2025 in “The Journal of Rheumatology” Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.
1 citations
,
May 2026 in “Nature Communications” CD19-CAR T cell therapy may help regenerate skin in systemic sclerosis.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
54 citations
,
February 2012 in “Pediatrics in Review” Pediatric systemic lupus erythematosus is a severe autoimmune disease in children requiring early diagnosis and comprehensive management.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.
2 citations
,
December 2021 in “Journal of Veterinary Medical Science” Lokivetmab reduced itching in a dog with skin lymphoma.
6 citations
,
January 2012 in “Journal of Biomedicine and Biotechnology” Ustekinumab might work for severe psoriasis, but more research is needed to be sure.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
November 2025 in “Skin Appendage Disorders” Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A new mutation in the STING protein causes a disease with lupus-like symptoms and responds well to a specific inhibitor treatment.
July 2025 in “Journal of Investigative Dermatology” Three molecular subtypes of advanced skin T-cell lymphoma were identified, with potential biomarkers for predicting treatment response and disease progression.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
October 2007 in “Revue du Rhumatisme”
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
3 citations
,
March 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.